Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
HOME > REGULATORY
REGULATORY
- MHLW Proposes Curbing Entries of Generic Makers That Threaten Stable Supplies
September 20, 2023
- 10-20% of Infected Adults Suffer Long COVID: MHLW Study
September 20, 2023
- Japan to End Use of Original COVID Vaccine, Previous Omicron Jabs
September 20, 2023
- Hamachi, Miyazaki Named Senior Vice Health Ministers
September 19, 2023
- Health Minister Set to Visit Boston Life Sciences Cluster
September 19, 2023
- Opposition Party Leader Raps Takemi’s Appointment as Health Minister
September 19, 2023
- Japan Grants Orphan Tag to Tafinlar/Mekinist, Retevmo
September 19, 2023
- Japan to Require Out-of-Pocket Cost for COVID Drugs from October
September 19, 2023
- New Health Minister Vows to Put Public Needs First in 2024 Drug Pricing Reform
September 15, 2023
- Japan to Basically Drop Japanese PI Requirement before Global Clinical Trials
September 14, 2023
- Chuikyo Mixed on Expanding Range of CEA Price Adjustments for Pricey Meds
September 14, 2023
- Bimzelx, Pivlaz Escape Price Cuts after Cost-Effectiveness Assessments
September 14, 2023
- Keizo Takemi Tapped as New Health Minister in Cabinet Reshuffle
September 14, 2023
- MHLW Must Take Big Step on Drug Lags, Losses in FY2024 Reform: Official
September 13, 2023
- University Hospital Reform Report Finds Inadequate Review of High-Price Drug Use
September 13, 2023
- Respond to Wage Hikes for Medical Workers in FY2024 Reform: Ex-Minister
September 13, 2023
- Japan’s Envisaged IP Tax Relief Likely to Cover Drug Sales, METI Eyes FY2024 Rollout
September 13, 2023
- Moderna’s Omicron XBB.1.5 Vaccine Snags Japan Approval
September 12, 2023
- New MHLW Drug Review Chief Vows to Make Japan Attractive Place for Clinical Trials, Watching Debate on Japanese PI
September 12, 2023
- New Working Group to Propose Effective Collection and Sharing of Drug Supply Info by March-End
September 12, 2023
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…